Intervention

Haloperidol

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 23 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials23

Recruiting0

Common conditions17

Lead sponsors shown15

Clinical trials

23 shown

A Study of Olanzapine in Patients With Acute AgitationNCT05803642 · 2023-03-28

Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of SchizophreniaNCT02240173 · 2017-06-01

Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With SchizophreniaNCT03075657 · 2017-05-01

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)NCT02600741 · 2015-07-24

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or SchizophreniformNCT02431702 · 2015-07-08

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsNCT02307396 · 2015-02-01

Pharmacovigilance in Gerontopsychiatric PatientsNCT02374567 · 2015-01-01

Lurasidone Effects on Tissue Glutamate in SchizophreniaNCT02199743 · 2013-02-01

Effects of Aripiprazole and Haloperidol on Mesolimbic System FunctioningNCT01161277 · 2010-08-01

Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in SchizophreniaNCT01164059 · 2010-02-01

Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With SchizophreniaNCT00838032 · 2008-08-01

Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of SchizophreniaNCT01052389 · 2007-07-01

Multicenter, Open-Label, Randomised, Haloperidol-controlled Study to Evaluate Seroquel as Mono-Therapy in the Treatment of Agitated Symptoms in the Patients With Acute Episode of SchizophreniaNCT00631722 · 2007-05-01

Metabolic Profile and Anthropometric Changes in SchizophreniaNCT00534183 · 2006-06-01

Long-Term Efficacy and Safety of Asenapine Using Haloperidol as a Positive Control (41513)(COMPLETED)(P05785)NCT00156065 · 2005-09-01

Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)NCT00156104 · 2005-07-01

Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With SchizophreniaNCT00485901 · 2004-07-01

Ziprasidone vs. Sertraline/Haloperidol in Psychotic DepressionNCT00340379 · 2003-04-01

Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological TherapyNCT00419653 · 2003-01-01

Clozapine and Olanzapine Treatment of AggressionNCT01123408 · 1999-06-01

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of SchizophreniaNCT00007774 · 1998-03-01

Clozapine Versus Haloperidol for Treating the First Episode of SchizophreniaNCT00169091 · 1996-03-01

Agitation in Alzheimer's DiseaseNCT00000179

Common conditions

Schizophrenia17 Schizoaffective Disorder2 Schizophrenia and Disorders With Psychotic Features2 Acute Agitation1 Acute Schizophrenia1 Affective Disorders1 Alzheimer Disease1 Anxiety Disorders1 Dementia1 Depression1 Diabetes1 Metabolic Syndrome1 Obesity1 Psychosis1 Psychosomatic Disorders1 Psychotic Disorders1 Schizoaffective Disorders1

Mapped diseases appearing in these trials

Shared study participation does not establish that this intervention treats a disease.

schizophrenia17 schizoaffective disorder2 abdominal obesity-metabolic syndrome1 Alzheimer disease1 dementia1 depressive disorder1 diabetes mellitus1 obesity disorder1 psychotic disorder1

Leading sponsors

Janssen Scientific Affairs, LLC 2 Organon and Co 2 All India Institute of Medical Sciences, Bhubaneswar 1 Central Institute of Psychiatry, Ranchi, India 1 Duke University 1 Eli Lilly and Company 1 Federal Neuro-Psychiatric Hospital, Yaba 1 Hannover Medical School 1 Harvard Medical School (HMS and HSDM) 1 Mario Negri Institute for Pharmacological Research 1 Nathan Kline Institute for Psychiatric Research 1 National Institute on Aging (NIA) 1 Oslo University Hospital 1 Peking University 1 Qilu Pharmaceutical Co., Ltd. 1

Trial status mix

COMPLETED17

TERMINATED3

UNKNOWN3

Phase mix

PHASE410

PHASE38

NA3

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.